FLGT News and Press, Fulgent Genetics Inc. From 10/17/23

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results bef...

2023-09-21 17:06:24 ET Summary Fulgent Genetics saw robust Q2 revenue growth at $68M but struggled with a GAAP loss of $11.2M, suggesting strategic investments. The firm boasts significant liquidity ($846.8M), allowing for potential acquisitions or growth initiatives, yet operatio...

2023-08-04 10:33:05 ET Fulgent Genetics, Inc. (FLGT) Q2 2023 Earnings Conference Call August 04, 2023, 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul K...

2023-08-04 07:12:10 ET Fulgent Genetics press release ( NASDAQ: FLGT ): Q2 Non-GAAP EPS of -$0.08 beats by $0.25 . Revenue of $67.85M (-45.9% Y/Y) beats by $5.37M . Adjusted EBITDA loss of $2.7 million. Generated cash flow from operations of $9.7 million. ...

Total Revenue of $68 million Record Core Revenue of $67 million, growth of 48% year-over-year Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a t...

2023-08-03 14:18:08 ET Fulgent Genetics ( NASDAQ: FLGT ) is scheduled to announce Q2 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is -$0.33 (-142.3% Y/Y) and the consensus Revenue Estimate is $62.48M (-50.2% Y/Y). Over the last...

2023-07-29 14:00:00 ET Summary Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential undervaluation, despite negative earnings forecasted t...

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Off...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its second quarter 2023 financial results be...

2023-06-06 07:45:00 ET If you're looking to invest $2,500 somewhere it'll grow, but you're a bit leery of buying an increasingly overpriced and hyped-up growth stock like Nvidia , Fulgent Genetics (NASDAQ: FLGT) might be up your alley. Its shares are priced for bargain hunters, ...